Market revenue in 2023 | USD 20.4 million |
Market revenue in 2030 | USD 264.9 million |
Growth rate | 44.3% (CAGR from 2023 to 2030) |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | |
Key market players worldwide | Novo Nordisk A/S ADR, GlaxoSmithKline, Novartis AG ADR, Icahn Enterprises LP Depositary Units Repr Units of LP Interests, Rhythm Pharmaceuticals Inc, PureTech Health PLC |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to anti-obesity medication market will help companies and investors design strategic landscapes.
Horizon Databook provides a detailed overview of country-level data and insights on the South Africa anti-obesity medication market , including forecasts for subscribers. This country databook contains high-level insights into South Africa anti-obesity medication market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account